首页> 外文期刊>Modern Pathology >Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas
【24h】

Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas

机译:淋巴内皮细胞标记物单克隆抗体D2-40与卡波济肉瘤和血管肉瘤亚群反应

获取原文
           

摘要

There is controversy over the histogenesis of Kaposi's sarcoma (KS) from lymphatic or blood vessel endothelium. D2-40 is a novel monoclonal antibody to an Mr 40,000 O-linked sialoglycoprotein that reacts with a fixation-resistant epitope on lymphatic endothelium. We sought to establish the selectivity of D2-40 for lymphatic endothelium in normal tissues and compare its reactivity with the expression of the widely used vascular endothelial marker CD31 in a series of 62 formalin-fixed and paraffin-embedded vascular lesions including KS. In normal tissues, D2-40 stained the endothelium of lymphatic channels but not of blood vessels, including arteries and capillaries defined by reactivity with the blood vessel endothelial marker PAL-E. In our series of vascular lesions, D2-40 stained lymphangiomas (10/10), benign tumors of undisputed lymphatic origin, but not benign neoplasms or tumorlike lesions of blood vessel origin, including hemangiomas (0/10), glomus tumors (0/3), angiolipomas (0/2), pyogenic granulomas (0/2), vascular malformations (0/2), hemangiopericytoma (0/1), or hemangioendothelioma (0/1). D2-40 stained all cases of cutaneous KS (24/24) at all stages of progression, including patch, plaque, and nodular stages, supporting the concept that this disease originates from a cell type capable of undergoing lymphatic differentiation. D2-40 also stained three of seven angiosarcomas, indicating that a subset of these tumors can undergo at least partial differentiation along the lymphatic endothelial lineage and could be classified as lymphangiosarcomas. In comparison, CD31 was expressed in all benign and malignant vascular lesions, except for glomus tumors (0/3) and 5/10 lymphangiomas, in which staining was absent. We conclude that D2-40 is a new selective marker of lymphatic endothelium in normal tissues and vascular lesions and is valuable for studying benign and malignant vascular disorders in routinely processed tissue specimens.
机译:关于卡波西氏肉瘤(KS)的淋巴或血管内皮组织形成存在争议。 D2-40是针对40,000 O先生连接的唾液糖蛋白的新型单克隆抗体,该蛋白与淋巴内皮细胞的抗固定表位反应。我们试图建立D2-40对正常组织中淋巴管内皮细胞的选择性,并将其反应性与62种福尔马林固定和石蜡包埋的血管病变(包括KS)中广泛使用的血管内皮标记CD31的表达进行比较。在正常组织中,D2-40染色了淋巴通道的内皮,但未染色血管的内皮,包括与血管内皮标记物PAL-E的反应性所定义的动脉和毛细血管。在我们的一系列血管病变中,D2-40染色的淋巴管瘤(10/10),无争议的淋巴源性良性肿瘤,但不是血管源性良性肿瘤或肿瘤样病变,包括血管瘤(0/10),肾小球肿瘤(0 / 3),血管脂肪瘤(0/2),化脓性肉芽肿(0/2),血管畸形(0/2),血管内皮细胞瘤(0/1)或血管内皮细胞瘤(0/1)。 D2-40在进展的所有阶段(包括斑块,斑块和结节阶段)对所有皮肤KS(24/24)病例进行了染色,支持了这种疾病源自能够进行淋巴分化的细胞类型的概念。 D2-40还对七个血管肉瘤中的三个进行了染色,表明这些肿瘤的一个子集可以沿淋巴管内皮细胞系至少部分分化,可以归类为淋巴管肉瘤。相比之下,CD31在所有良性和恶性血管病变中均有表达,除了球囊肿瘤(0/3)和5/10淋巴管瘤除外,它们均不染色。我们得出的结论是,D2-40是正常组织和血管病变中淋巴管内皮的新选择标记,对于研究常规处理的组织标本中的良性和恶性血管疾病具有重要价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号